TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Behavioral Insights to Encourage Judicious Prescribing of Opioids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
The investigators will not be enrolling subjects. This is an evaluation of a public health intervention involving sending prescriber's factual and nonjudgmental letters, signed by the County Medical Examiner, that would state that a patient the provider had treated with controlled substances died of an opioid poisoning.~Inclusion Criteria:~* Prescribers in California for whom at least one of their prescription(s) was filled by a patient who died of an opioid poisoning in San Diego County~Exclusion Criteria:~* Prescriber is licensed outside the State of California and does not hold a California license, but the prescription was filled in California~* The prescriber does not have a CURES report on record~* The prescriber has issued only one opioid prescription in the last 12 months since the time of the deceased death (and the prescription was to the deceased)~* Prescribers with unknown Drug Enforcement Agency number

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Letter intervention (Type: EXPERIMENTAL): The intervention arm will involve letters sent to prescribers in San Diego County.
- Control (Type: NO_INTERVENTION): The control group will involve prescribers not receiving letters

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Both sex~* Age \> 1 year~* Fever (axillary temp ≥ 37.5oC) or history of fever during the preceding 48 hours~* Uncomplicated Plasmodium vivax confirm by microscopic examination~* Asexual parasite ≥ 250/µL blood~* Absence of clinical condition that need hospitalization~* No history of allergy to antimalarial drug~* Not consuming antibiotic with antimalarial activity~Exclusion Criteria:~* Clinical features of severe malaria~* Severe malnutrition~* Recurrent vomiting~* Concomitant infection~* Pregnant (test for β-HCG in women of child bearing age)~* Lactating mother~* Move out from study area~* Not eligible to follow up during study period

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DHP+PQ (Type: EXPERIMENTAL): Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
- AS-AQ +PQ (Type: ACTIVE_COMPARATOR): Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must understand and voluntarily sign an informed consent form.~* Age ≥ 20 years at the time of signing the informed consent form.~* Must be able to adhere to the study visit schedule and other protocol requirements.~* Diagnosis of Myelodysplastic Syndrome (MDS) that meets International Prognostic Scoring System (IPSS) criteria for low- or intermediate-1-risk disease associated with a deletion 5(q31-33) abnormality~* Symptomatic anemia secondary to MDS defined as:Untransfused Hb level \< 10.0 g/dL and a Functional Assessment of Cancer Therapy (FACT)-anemia subscale score of ≤ 74 or Transfusion dependent anemia~Exclusion Criteria:~* Pregnant or lactating females.~* Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.~* Prior therapy with lenalidomide.~* Patients with any of the following laboratory abnormalities within 14 days of starting study drug: Absolute Neutrophil Count (ANC) \< 750 cells/μL (0.75 x 10\^9/L) Platelet count \< 50,000/μL (50x10\^9/L) Serum creatinine \> 2.5 mg/dL Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) \> 3.0 x Upper Limit of Normal (ULN)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide (Type: EXPERIMENTAL): Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Tissue from an archived or fresh tumor sample~* A peripheral blood buffy coat sample is required for CLL/SLL.~* Patient has mantle cell lymphoma (MCL), follicular lymphoma (FL), or chronic lymphocytic leukemia (CLL)/SLL or diffuse large B cell lymphoma~* Patient \> or = 18 years old~* Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2. Patients with DLBCL will have ECOG \< or = 1~* Adequate white blood cells and hemoglobin~* Good kidney and liver function~* Fasting glucose \< 160 mg/dL~* No other malignancy~* Use of adequate birth control~Exclusion criteria:~* Treatment with cytotoxic chemotherapy, biologic agents, investigational therapies within 4 weeks, or nitrosoureas or mitomycin C within 6 weeks of study enrollment~* Treatment with a small-molecule kinase inhibitor within 2 weeks, or 5 half lives of the drug or its active metabolites (whichever is longer) of study enrollment~* Prior treatment with a PI3K, mTOR, or Akt inhibitor. Prior treatment of MCL with temsirolimus is permitted in patients enrolled from countries where it is licensed for this indication.~* Radiation therapy within 2 weeks of enrollment~* Autologous stem cell transplantation within 16 weeks of enrollment~* Prior allogeneic transplantation except for patients with R/R DLBCL who meet inclusion criteria~* Central nervous system (CNS) or leptomeningeal involvement. Patients with DLBCL may have active CNS or leptomeningeal involvement.~* Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (anti-HCV) serology~* Primary CNS lymphoma~* Primary mediastinal B-lymphoma~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mantle cell (Type: EXPERIMENTAL): 50 mg twice daily: no eating for 2 hours prior and 1 hour after dose
- follicular lymphoma (Type: EXPERIMENTAL): 50 mg twice daily: no eating for 2 hours prior and 1 hour after dose
- CLL/SLL (Type: EXPERIMENTAL): 50 mg twice daily:no eating for 2 hours prior and 1 hour after dose
- Diffuse large B cell lymphoma (Type: EXPERIMENTAL): 50 mg twice daily:no eating for 2 hours prior and 1 hour after dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Antibiotic Prophylaxis for Endophthalmitis Following Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients, including diabetics, undergoing routine cataract surgery in each unit taking part in the study~Exclusion Criteria:~* Patients who do not wish to take part in the trial~* Patients allergic to penicillins and cephalosporins.~* Long-term nursing home patients~* Patients with only one eye~* Pregnancy.~* Children less than 18 years old.~* All severely 'at-risk' groups for infection including:~  * Severe atopic keratoconjunctivitis;~ * Severe active blepharitis;~ * Ocular cicatricial pemphigoid.~* Patients with complicated cataracts such as traumatic or subluxated~* Patients having combined operations with cataract surgery such as trabeculectomy or a corneal graft.~* Patients known to be allergic to povidone iodine (very rare) or any other known hypersensitivity to any components of the study medications.~* Patients who are incapacitated mentally and incapable of giving consent.~* Patients with severe thyroid disease~* Open infection anywhere, infection of lacrimal drainage channels or infection around the eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women with primary breast cancer who are candidates for radical surgery.~* Breast tumours clinically ≥ 15 mm, Nx, M0.~* Breast tumours identified on mammography and verified on fine needle aspiration.~* Age \> 18 years.~* Performance status of ECOG ≤ 1.~* Laboratory requirements at the day of diagnosis (t1-):Prior to inclusion a normal renal (serum creatinine) and hepatic (transaminases) function (within normal limits) estimated in blood samples is required.~* Prior to patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.~* Negative pregnancy test for pre menopausal women before inclusion in the trial~Exclusion Criteria:~* Ongoing cholesterol lowering therapy (statins, fibrates, ezetimibe).~* Prior breast cancer treatment.~* Current HRT.~* Known liver disease.~* History of hemorrhagic stroke.~* Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; these conditions will be discussed with the patient before registration in the trial.~* History of allergic reactions attributed to compounds of similar chemical or biological composition to atorvastatin.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males, \>=12 years of age.~* Severe hemophilia A or B without inhibitors.~  * Severity confirmed by a central laboratory where FVIII level was less than (\<) 1 percent (%) or Factor IX (FIX) level was less than or equal to (\<=) 2% at Screening.~ * On-demand use of factor concentrate to manage bleeding episodes for at least the last 6 months prior to Screening, and meet each of the following criterion:~    * Nijmegen modified Bethesda assay inhibitor titer of \<0.6 Bethesda units per milliliter (BU/mL) at Screening.~   * No use of Bypassing agents to treat bleeding episodes for at least the last 6 months prior to Screening.~   * No history of immune tolerance induction therapy within the last 3 years prior to Screening.~* A minimum of 6 bleeding episodes requiring factor concentrate treatment within the last 6 months prior to Screening.~* Willing and complied with the study requirements and to provide written informed consent and assent.~Exclusion Criteria:~* Known co-existing bleeding disorders other than hemophilia A or B, i.e., Von Willebrand's disease, additional factor deficiencies, or platelet disorders.~* Antithrombin (AT) activity \<60% at Screening.~* Co-existing thrombophilic disorder.~* Clinically significant liver disease.~* Active hepatitis C virus infection.~* HIV positive with a cluster of differentiation-4 count of \<200 cells/microliter.~* History of arterial or venous thromboembolism.~* Inadequate renal function.~* History of multiple drug allergies or history of allergic reaction to an oligonucleotide or N-Acetylgalactosamine (GalNAc).~* History of intolerance to SC injection(s).~* Any other conditions or comorbidities that would make the participant unsuitable for enrollment or could interfere with participation in or completion of the study, per Investigator judgment.

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Factor On-demand (Type: EXPERIMENTAL): Participants received on-demand factor concentrates (as needed, for episodic bleeding episodes, and not on a regular regimen intended to prevent spontaneous bleeding) per Investigator discretion for the treatment of breakthrough bleeding episodes from Day 1 up to a total of 9 months.
- Fitusiran 80 mg Prophylaxis (Type: EXPERIMENTAL): Participants received open-label fitusiran 80 milligram (mg) administered subcutaneously (SC) as prophylaxis once monthly from Day 1 up to a total of 9 months. Participants received on-demand factor concentrates (per investigator's discretion and within bleeding dosing guidelines) for the treatment of breakthrough bleeding episodes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects with signs or symptoms consistent with infection, and if available, laboratory findings consistent with staphylococcal infection (e.g., Gram stain and culture results).~* Signs and symptoms consistent with infection~* Infection suspected to be due to Methicillin Resistant Staphylococcus Aureus~Exclusion Criteria:~* Subjects who were treated with a previous antibiotic (systemic or topical) with MRSA activity (other than linezolid or vancomycin) for more than 24 hours and treatment extended into the 72 hour period prior to the first dose of study drug, unless documented to be a treatment failure (72 hours of treatment and not responding).~* Subjects with uncomplicated skin or superficial skin structure infection such as superficial/simple cellulitis, impetiginous lesion, furuncle, or simple abscess that only need surgical drainage for cure.~* Subjects excluded with necrotizing fasciitis, gas gangrene, osteomyelitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 8-19 years old~* Subject able to give assent, and parent/guardian capable of giving consent on behalf of the child~* Body mass index (BMI) ≥ 99th percentile (based on gender and age)~Exclusion Criteria:~* Type 1 or 2 diabetes mellitus~* Initiation of a new drug therapy within the past 30 days prior to the screening visit~* BMI ≥ 55~* History of weight loss surgery~* Obesity from a genetic cause (e.g., Prader-Willi)~* Central nervous system injury or severe neurological impairment~* Known systolic or diastolic dysfunction or heart failure~* Females who are currently pregnant or planning to become pregnant~* Liver enzymes \> 2.5 times upper limit of normal~* Severe renal impairment (defined as creatinine clearance \<30 mL/min)~* Gastrointestinal disease

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): Exenatide
- Control (Type: NO_INTERVENTION): Control - no intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dehydroepiandrosterone Supplementation for Poor Responder Patients During in Vitro Fertilization Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* previous poor response to ovarian stimulation in IVF.~Exclusion Criteria:~* patients over the age of 42~* patients who received DHEA at any time.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- DHEA supplementation (Type: EXPERIMENTAL): DHEA was added to induction of ovulation by recombinant FSH and recombinant LH, in IVF long protocol
- only induction of ovulation by same long protocol without DHEA (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with uncurable metastatic carcinoma, lymphoma, or sarcoma.~* ECOG performance status 0, 1, 2~* No active bleeding~* No clinical coagulopathy~* Anticipated lifespan greater than 12 weeks~Exclusion Criteria:~* Active residual toxicity from prior therapies~* Active Infection~* HIV positive~* Hepatitis B or C positive~* Pregnant or nursing women~* Requirement for oral steroids~* Brain metastases~* Presence or history of autoimmune disease~* Shellfish or tetanus allergy~* Splenomegaly~* Lymph nodes greater than 10 cm in maximal diameter~* Uncontrolled angina or class II or IV heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KLH + anti-OX40 (Type: EXPERIMENTAL): Day 1: KLH + anti-OX40; Day 3: anti-OX40; Day 4: anti-OX40; Day 29: Tetanus vaccine
- Tetanus vaccine + anti-OX40 (Type: EXPERIMENTAL): Day 1: Tetanus vaccine + anti-OX40; Day 3: anti-OX40; Day 5: anti-OX40; Day 29: KLH

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ca:Mg Ratio and Cognitive Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants from our parent study (Personalized Prevention of Colorectal Cancer Trial, NCT#01105169, IRB#100106);~2. Participants who completed the MoCA~Exclusion Criteria:~1. Participants did not provide their blood samples in the parent study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- magnesium treatment (Type: ACTIVE_COMPARATOR): Participants will be assigned to magnesium glycinate
- placebo (Type: PLACEBO_COMPARATOR): Participants will be assigned to placebo group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be 2 - 45 years of age and at least 10 kg~* Must have clinically severe SCD (SS, SC or SBeta0 Thal) or thalassemia major and be eligible for myeloablative SCT~* Must have two partially HLA-matched CBUs for part 1; and one partially HLA-matched CBU for part 2~* Back-up autologous stem cells harvested from bone marrow~* Adequate Karnofsky Performance score or Lansky Play-Performance scale~* Sufficient physiological reserves~* Signed written informed consent~Exclusion Criteria:~* HLA-matched related donor able to donate~* Severe alloimmunization with inability to guarantee a supply of adequate PRBC donors~* Prior allogeneic hematopoietic SCT within the last 12 months or reduced-intensity transplant within the past 6 months~* Human immunodeficiency virus (HIV) infection~* Active or uncontrolled infection~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- NiCord (Type: EXPERIMENTAL): NiCord: NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete